Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 18/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | POLQ | O75417 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3802998 | 0.91 | CFTR (0.52) | CFTRPDE4DNR1I2ADORA3CYP2C8 | |
| SCHEMBL3672859 | 0.90 | CFTR (0.55) | CFTRPDE4DNR1I2ADORA3CYP2C8 | |
| SCHEMBL14038146 | 0.89 | CFTR (0.53) | CFTRPDE4DNR1I2ADORA3CYP2C8 | |
| SCHEMBL3803176 | 0.87 | CFTR (0.51) | CFTRPDE4DNR1I2ADORA3CYP2C8 | |
| SCHEMBL3672957 | 0.86 | CFTR (0.57) | CFTRPDE4DNR1I2ADORA3CYP2C8 | |
| SCHEMBL12189097 | 0.86 | CFTR (0.64) | CFTRPDE4DNR1I2ADORA3CYP2C8 | |
| SCHEMBL3671482 | 0.85 | CFTR (0.67) | CFTRPDE4DNR1I2ADORA3CYP2C8 | |
| SCHEMBL16351207 | 0.85 | CFTR (0.57) | CFTRPDE4DNR1I2ADORA3CYP2C8 | |
| SCHEMBL12189333 | 0.85 | CFTR (0.64) | CFTRPDE4DNR1I2ADORA3CYP2C8 | |
| SCHEMBL3636612 | 0.85 | PIK3CA (0.38) | CFTRPDE4DNR1I2ADORA3CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150166516-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-06-18 | — | — | US | disclosed |
| US-8969386-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150031708-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166516-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | CFTR 1/4885PDE4D 431/4885NR1I2 889/4885 |
| US-20150031708-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | CFTR 1/4885PDE4D 431/4885NR1I2 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.